Last reviewed · How we verify
LG002
At a glance
| Generic name | LG002 |
|---|---|
| Also known as | ICIs |
| Sponsor | Zhen-Yu Ding |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs (EARLY_PHASE1)
- Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LG002 CI brief — competitive landscape report
- LG002 updates RSS · CI watch RSS
- Zhen-Yu Ding portfolio CI